TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Warning Labels Decrease Soda Purchasing?
Brief Summary: Investigators will run a field study evaluating the impact different labels have on the purchasing of sugar sweetened beverages. This field study will take place in a hospital cafeteria.


Options:
A: Arm Label: Calorie Label; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: Warning Label; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: Warning Label with Graphics; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: No label; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Label Condition; Assigned to Arm(s): Calorie Label, Warning Label, Warning Label with Graphics
B: Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback letters | Arm Label: Feedback plus incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback plus incentives | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback letters; Assigned to Arm(s): Feedback only | Intervention Type: BEHAVIORAL; Name: Feedback plus incentives; Assigned to Arm(s): Feedback plus incentives
C: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
D: Arm Label: Targeted beverage education and financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Targeted beverage education and financial incentives, Behavioral: Traffic-light labeling of all beverages in store | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Behavioral: Traffic-light labeling of all beverages in store | Intervention Type: BEHAVIORAL; Name: Targeted beverage education and financial incentives; Assigned to Arm(s): Targeted beverage education and financial incentives | Intervention Type: BEHAVIORAL; Name: Traffic-light labeling of all beverages in store; Assigned to Arm(s): Control, Targeted beverage education and financial incentives

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Non Surgical Treatment of Periodontitis on Glycaemic Control in a Type 2 Diabetic Populations of Cameroon
Brief Summary: The aim of this study is to investigate the effects of non-surgical periodontal treatment on the metabolic control of type2 diabetes patients. Patients with type two diabetes mellitus patients and confirmed chronic periodontitis will be selected and randomly assign to two groups. The treatment group will receive immediate full-mouth scaling and root planing whereas the control group will be scheduled to receive periodontal treatment at the following 3-month visit. Plaque index, bleeding index, probing pocket depth, recessions and cervical attachment loss will be recorded at baseline, at six weeks and at three months. Glycated haemoglobin (HbA1c) and C-reactive protein (CRP) will be analysed at baseline and three months following enrolment.


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Procedure: non-surgical periodontal treatment | Arm Label: control; Type: OTHER; Interventions: Procedure: non-surgical periodontal treatment | Intervention Type: PROCEDURE; Name: non-surgical periodontal treatment; Assigned to Arm(s): control, treatment
B: Arm Label: Non-surgical periodontal therapy; Type: EXPERIMENTAL; Interventions: Procedure: Non-surgical periodontal therapy | Arm Label: Delayed non-surgical periodontal therapy; Type: OTHER; Interventions: Other: Delayed non-surgical periodontal therapy | Intervention Type: PROCEDURE; Name: Non-surgical periodontal therapy; Assigned to Arm(s): Non-surgical periodontal therapy | Intervention Type: OTHER; Name: Delayed non-surgical periodontal therapy; Assigned to Arm(s): Delayed non-surgical periodontal therapy
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Procedure: Periodontal Scaling and root planing | Intervention Type: PROCEDURE; Name: Periodontal Scaling and root planing; Assigned to Arm(s): intervention
D: Arm Label: Nonsurgical periodontal therapy; Type: EXPERIMENTAL; Interventions: Procedure: Nonsurgical periodontal therapy, Procedure: Oral hygiene instructions | Arm Label: Oral hygiene instructions; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Oral hygiene instructions | Intervention Type: PROCEDURE; Name: Nonsurgical periodontal therapy; Assigned to Arm(s): Nonsurgical periodontal therapy | Intervention Type: PROCEDURE; Name: Oral hygiene instructions; Assigned to Arm(s): Nonsurgical periodontal therapy, Oral hygiene instructions

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial
Brief Summary: Atrial fibrillation (AF) is the most common heart rhythm disease characterized by an irregular heart rhythm of the top part (atria) of the heart. It may cause unpleasant symptoms as well as increases the person's risk of stroke and heart failure. With an ageing population, increasing rates of AF and limited access to specialists, new methods of care, like nurse practitioners (NP) need to be assessed to meet patient specific needs and provide sustainable care.

The objective of the project is to evaluate the effect of Nurse Practitioner-led care in people with AF on their quality of life.

The Canadian Healthcare system is overwhelmed, with increasing costs and wait times. Contributing to these issues, is AF is the most common arrhythmia accompanied with costly complications including stroke and heart failure. Currently family or emergency room physicians ask general cardiologists or specialized cardiologists, to provide care to patients with AF. Unfortunately, there is limited access to their services. NP's are nurses who have taken extra education at University to treat patients and prescribe medications. This research project involves an NP who has specialized training in AF patient management.

By utilizing an NP to provide care for patients with AF, the investigators hope to improve patient's quality of life and satisfaction with care. This may also reduce complications of AF.


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
B: Arm Label: Nurse Practitioner Led-Care; Type: EXPERIMENTAL; Interventions: Other: Nurse Practitioner Led-Care | Arm Label: Cardiologist Led-Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Cardiologist Led-Care | Intervention Type: OTHER; Name: Nurse Practitioner Led-Care; Assigned to Arm(s): Nurse Practitioner Led-Care | Intervention Type: OTHER; Name: Cardiologist Led-Care; Assigned to Arm(s): Cardiologist Led-Care
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-coordinated integrated care model for AF | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nurse-coordinated integrated care model for AF; Assigned to Arm(s): Intervention group
D: Arm Label: Specialized AF-clinic; Type: EXPERIMENTAL; Interventions: Other: Specialized outpatient AF Clinic | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Specialized outpatient AF Clinic; Assigned to Arm(s): Specialized AF-clinic | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing the Feasibility of Integrating Maternal Nutrition Interventions Into an Existing Maternal, Newborn, and Child Health Platform in Bangladesh: A Cluster-randomized Operational Evaluation
Brief Summary: Inadequate maternal nutrition is likely to undermine the potential impact of infant and young child feeding (IYCF) improvements made in the Alive \& Thrive (A\&T) first phase because it is linked to poor fetal growth leading to small-for-gestational age and pre-term newborns. These babies do not respond to growth promoting feeding practices as well as normal newborns do. In Phase 2, Alive \& Thrive decided to focus on integrating a package of maternal nutrition interventions in a large-scale maternal, newborn and child health program (MNCH). This proposed evaluation aims to assess the feasibility of integrating maternal nutrition interventions into an existing MNCH platform in Bangladesh, using a cluster-randomized evaluation design.


Options:
A: Arm Label: A&T- intensive; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal Nutrition Behavior change | Arm Label: A&T-non intensive; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Maternal Nutrition Behavior change; Assigned to Arm(s): A&T- intensive
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Simulation breastfeeding education | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Simulation breastfeeding education; Assigned to Arm(s): Intervention Group
D: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.
Brief Summary: The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority open label randomized multicenter trial with blinded adjudication of outcome events.


Options:
A: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
B: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Dabigatran Etexilate 110mg; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran Etexilate 110mg, Drug: Clopidogrel or Ticagrelor | Arm Label: Dabigatran Etexilate 150mg; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran Etexilate 150mg, Drug: Clopidogrel or Ticagrelor | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin 3mg, Drug: Aspirin, Drug: Clopidogrel or Ticagrelor, Drug: Warfarin 5mg, Drug: Warfarin 1mg | Intervention Type: DRUG; Name: Dabigatran Etexilate 110mg; Assigned to Arm(s): Dabigatran Etexilate 110mg | Intervention Type: DRUG; Name: Warfarin 3mg; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran Etexilate 150mg; Assigned to Arm(s): Dabigatran Etexilate 150mg | Intervention Type: DRUG; Name: Clopidogrel or Ticagrelor; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel or Ticagrelor; Assigned to Arm(s): Dabigatran Etexilate 110mg | Intervention Type: DRUG; Name: Warfarin 5mg; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel or Ticagrelor; Assigned to Arm(s): Dabigatran Etexilate 150mg | Intervention Type: DRUG; Name: Warfarin 1mg; Assigned to Arm(s): Warfarin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.
Brief Summary: The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority open label randomized multicenter trial with blinded adjudication of outcome events.


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin
C: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
D: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Randomized Controlled Trial of a "Freeze All and Transfer Later" Versus a Conventional "Fresh Embryo Transfer" Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle
Brief Summary: The purpose of this study is to compare conventional fresh embryo transfer with a "freeze all and transfer later strategy" in assisted reproductive technology in terms of ongoing pregnancy rates, live birth rates as well as perinatal outcomes.


Options:
A: Arm Label: Fresh transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: fresh transfer | Arm Label: Deferred-frozen embryo transfer; Type: EXPERIMENTAL; Interventions: Procedure: Deferred-frozen embryo transfer | Intervention Type: PROCEDURE; Name: fresh transfer; Assigned to Arm(s): Fresh transfer | Intervention Type: PROCEDURE; Name: Deferred-frozen embryo transfer; Assigned to Arm(s): Deferred-frozen embryo transfer
B: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
C: Arm Label: Freeze all; Type: EXPERIMENTAL; Interventions: Procedure: Freeze all | Arm Label: Fresh embryo transfer; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Freeze all; Assigned to Arm(s): Freeze all
D: Arm Label: Day 3 eSET combined with Eeva; Type: ACTIVE_COMPARATOR; Interventions: Device: Eeva™ results | Arm Label: Day 5 eSET combined with Eeva; Type: ACTIVE_COMPARATOR; Interventions: Device: Eeva™ results | Arm Label: Day 5 eSET with Traditonal Morphology; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Eeva™ results; Assigned to Arm(s): Day 3 eSET combined with Eeva, Day 5 eSET combined with Eeva

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Randomized Controlled Trial of a "Freeze All and Transfer Later" Versus a Conventional "Fresh Embryo Transfer" Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle
Brief Summary: The purpose of this study is to compare conventional fresh embryo transfer with a "freeze all and transfer later strategy" in assisted reproductive technology in terms of ongoing pregnancy rates, live birth rates as well as perinatal outcomes.


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: Freeze all; Type: EXPERIMENTAL; Interventions: Procedure: Freeze all | Arm Label: Fresh embryo transfer; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Freeze all; Assigned to Arm(s): Freeze all
C: Arm Label: Frozen Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Arm Label: Fresh Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Intervention Type: OTHER; Name: PGD; Assigned to Arm(s): Fresh Embryo Transfer with PGD, Frozen Embryo Transfer with PGD
D: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.
Brief Summary: A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Dimethyl Fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl fumarate, Drug: Sodium Chloride solution | Arm Label: Sodium Chloride solution; Type: SHAM_COMPARATOR; Interventions: Drug: Dimethyl fumarate, Drug: Sodium Chloride solution | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Dimethyl fumarate; Assigned to Arm(s): Dimethyl Fumarate, Sodium Chloride solution | Intervention Type: DRUG; Name: Sodium Chloride solution; Assigned to Arm(s): Dimethyl Fumarate, Sodium Chloride solution
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo
C: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: A